Immunicum AB gets green light for Phase I/II trial

17.12.11 Gothenburg – The Swedish Medical Products Agency has given Sweden’s Immunicum AB the green light for a Phase I/II trial of the firm’s kidney cancer vaccine, which is based on dendritic cells from healthy individuals. The study... more

Tibotec and BMS combine HCV approaches

16.12.11 Tibotec Pharmaceutical Ltd (Dublin) and Bristol-Myers Squibb (BMS) have announced they will launch a Phase II trial in 2012 in patients with chronic hepatitis C infections. The companies are testing a combination therapy of BMS’... more

Progress with HCV programme

16.12.11 French Cytheris SA (Paris) has presented positive interim data from a Phase I/IIa study with its Interleukin 7 treatment Cyt107 in patients with hepatitis C who do not respond to standard of care (SOC). Following treatment with... more

Good response rate

15.12.11 German CureVac GmbH (Tübingen) has presented results from its Phase I/IIa dose escalation trial in non-small cell lung cancer (NSCLC) with its mRNA-based cancer vaccine CV9201 in patients with NSCLC stage IIIB/IV after first-line... more

Evolva's EV-077 starts into Phase II trials

15.12.11 Swiss Evolva Holding SA (Reinach) has been given the green light by regulatory authorities to move its oral thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 into Phase IIa clinical studies for diabetes... more